首页> The oncologist> Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Emilie M J,van Brummelen

第一单位： Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

作者： Emilie M J,van Brummelen ^[1] ; Sanne,Huijberts ^[1] ; Carla,van Herpen ^[2] ; Ingrid,Desar ^[2] ; Frans,Opdam ^[3] ; Robin,van Geel ^[4] ; Serena,Marchetti ^[3] ; Neeltje,Steeghs ^[3] ; Kim,Monkhorst ^[5] ; Bas,Thijssen ^[6] ; Hilde,Rosing ^[6] ; Alwin,Huitema ^[7] ; Jos,Beijnen ^[8] ; Rene,Bernards ^[9] ; Jan,Schellens ^[10]

作者单位： Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[1] Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. ^[2] Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[3] Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.;Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands. ^[4] Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[5] Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[6] Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.;Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ^[7] Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.;Utrecht University, Utrecht, The Netherlands. ^[8] Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.;Utrecht University, Utrecht, The Netherlands. ^[9] Utrecht University, Utrecht, The Netherlands. ^[10]

关键词 Afatinib Colorectal cancer KRAS Non-small cell lung cancer Pancreatic cancer Selumetinib